Advanced Search

 

Study ID Status Title Patient Level Data
TDU3166 Completed A study to investigate the safety, pharmacokinetics and pharmacodynamics (PD) of ORG31540/SR90107A administered as a single intravenous drip to healthy male volunteers
TDU4089 Completed A safety, pharmacokinetics and bioavailability study after single dose subcutaneous administration of Org31540/SR90107A 0.75, 2.5, and 8mg in young adult Japanese healthy male subjects.
TDU4289 Completed A safety and pharmacokinetics study after single dose subcutaneous administration of Org31540/SR90107A 2.5mg in elderly Japanese healthy male volunteers.
THRS/79/0010 (Well 18) Completed Examination of bupropion and diazepam, alone and in combination on human performance tests, subjective rating scales, EEG and autonomic responses.
THRS/81/0012 (Well 07B) Completed Pharmacokinetics in normal volunteers.
THRS/81/0023 (Well 20UK) Completed Effects of low doses of bupropion on plasma prolactin and growth hormone in normal subjects.
THRS/91/0011 (UK19) Completed An Evaluation of the Bioavailability of 250 mg LAMICTAL® Tablets in Normal Volunteers
THRS/91/0023 (UK72) Completed Lamotrigine Pharmacokinetics in Healthy Elderly Volunteers
THRS/91/0025 Completed The Pharmacokinetics of Lamotrigine (BW 430C) in Healthy Subjects with Unconjugated Hyperbilirubinemia (Gilbert’s Syndrome)
THRS/91/0045 Completed Steady-State Pharmacokinetic Study of Lamictal® in Healthy Volunteers Receiving Chronic Doses of Valproic Acid
TMT106386 Completed A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge-induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects with Social Anxiety Disorder Study Listed on ClinicalStudyDataRequest.com
TOC100224 Completed An observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Fusidic acid cream Applied Three Times daily for 7 days in the Treatment adult and paediatric subjects with Impetigo Study Listed on ClinicalStudyDataRequest.com
TOC103469 Completed A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment versus Placebo Ointment Applied Twice Daily for 5 days in the Treatment of Adults and Paediatric Subjects with Impetigo. Study Listed on ClinicalStudyDataRequest.com
TOC106489 Completed An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Study Listed on ClinicalStudyDataRequest.com
TOC110977 Completed A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects with SITL Study Listed on ClinicalStudyDataRequest.com
TP552001 Completed A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.
TP552002 Completed A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of a New Chemical Entity for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis.
TPD102031 Completed A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X cream on the Skin of Patients with Atopic Dermatitis
TPD103280 Completed Randomised, double-blind, placebo-controlled study of topical GW842470X formulation in adults with moderate atopic dermatitis
TPL102357 Completed A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, and 75mg once daily for 12 weeks in subjects with chronic hepatitis C-related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin.
TPL103922 Completed Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin)
TPL104054 Terminated Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures
TPL108390 Completed Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)
TRA100773 Completed A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenic purpura
TRA100773_B Completed A double-blind, randomized, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenic purpura

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.